Lupin’s Goa plant completes successful inspection by UK MHRA

Pharma major Lupin said its Goa facility has successfully completed an inspection by the UK Medicines and Healthcare Products Regulatory Authority.

“There were no critical or major observations in the inspection,” it said, indicating that products made at the facility can continue to be sold in the UK market.

This is not the first such inspection by the UK MHRA at the Goa plant.

Last year, US FDA inspectors had found “significant violations of current good manufacturing practice” at the company’s Goa plant.

Lupin is the sixth largest generics pharmaceutical company by sales globally and the second biggest pharma company in India.

It manufactures branded & generic formulations, biotechnology products and APIs or active pharmaceutical ingredients.

The company focuses on Cardiovascular, Diabetology, Asthma, Pediatric, CNS, Gl, Anti-infective and NSAID space and has sales of 171,198 million (USD 2.55 bilion) per year.